DelveInsight’s ‘Systemic Lupus Erythematosus – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Systemic Lupus Erythematosus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
Systemic Lupus Erythematosus Understanding
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease. The disease has a highly variable course and prognosis. The term lupus has been used to identify a number of chronic, autoimmune diseases that can damage any part of the body (such as skin, joints, and/or organs inside the body).
The DelveInsight Systemic Lupus Erythematosus epidemiology report gives a thorough understanding of the Systemic Lupus Erythematosus by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Systemic Lupus Erythematosus in the US, Europe, and Japan. The report covers the detailed information of the Systemic Lupus Erythematosus epidemiology scenario in seven major countries (US, EU5, and Japan).
Systemic Lupus Erythematosus Epidemiology
The Systemic Lupus Erythematosus epidemiology division provide insights about historical and current Systemic Lupus Erythematosus patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
As per DelveInsight estimates, total diagnosed prevalent cases of SLE in the 7MM was found to be 484,213 in 2017. Among all the countries, the estimates show higher population of SLE in the United States with 259,474 cases in 2017.
Systemic Lupus Erythematosus Epidemiology Segmentation
The epidemiology segment also provides the Systemic Lupus Erythematosus epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- Total Diagnosed Prevalent cases of SLE in 7MM
- Gender-Specific cases of SLE in 7 MM
- Severity-Specific cases of SLE in 7MM
- Treatable cases of SLE in 7MM
- 11-Year Forecast of Systemic Lupus Erythematosus epidemiology
- 7MM Coverage
- Total Cases of Systemic Lupus Erythematosus
- Total Cases of Systemic Lupus Erythematosus according to segmentation
- Diagnosed cases of Systemic Lupus Erythematosus
Table of contents
1. Key Insights
2. Executive Summary of Systemic Lupus Erythematosus
3. Systemic Lupus Erythematosus: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
5.3. Epidemiology Scenario: 7MM
5.4. United States Epidemiology
5.5. EU-5 Country-wise Epidemiology
5.6. Japan Epidemiology
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
10. DelveInsight Capabilities
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States